Abstract 16430: Association of Oral Anticoagulation with Long-Term Outcomes in New-Onset Atrial Fibrillation After ST-Elevation Myocardial Infarction: A Propensity-Score-Matched Cohort Study
Abstract
Background. New-onset atrial fibrillation (NOAF) after ST-elevation myocardial infarction (STEMI) is associated with excess mortality, but US population-scale data on oral anticoagulation (OAC) use and long-term outcomes in this population are limited. Methods. In the TriNetX US Collaborative Network, we identified adults with STEMI who had a first recorded diagnosis of atrial fibrillation or atrial flutter within 30 days of the index event in the available network record. OAC initiation within 30 days was compared with no recorded OAC using 1:1 propensity-score matching on prespecified covariates. Results. Among 36,965 eligible patients, OAC was prescribed to 36%; 10,566 pairs were matched. At 3 years, OAC was associated with lower all-cause mortality (15.2% vs 28.8%; HR 0.47, 95% CI 0.44-0.50; P<0.001), with absolute risk reduction 13.6 percentage points and number needed to treat of 7. The mortality association emerged at 30 days (HR 0.26, 95% CI 0.24-0.29; P<0.001) and persisted at 1 year (HR 0.40, 95% CI 0.37-0.43; P<0.001). Ischemic stroke did not differ at 3 years (4.1% vs 4.0%; HR 0.94, 95% CI 0.82-1.09; P=0.40). Major bleeding (6.8% vs 6.3%; P=0.71) and intracranial hemorrhage (1.4% vs 1.3%; P=0.76) were similar. Conclusions. In this US retrospective cohort of patients with documented NOAF after STEMI, OAC initiation within 30 days was associated with lower 3-year mortality without a statistically significant increase in coded major bleeding or intracranial hemorrhage. These findings highlight substantial treatment variation and support prospective studies to define optimal antithrombotic management in this population.